| Name | Title | Contact Details |
|---|
Whisper is a team of artificial intelligence, hearing care, hardware, and software experts coming together to solve the challenge of providing better hearing. We set out to make the Whisper Hearing System so our parents, grandparents, friends, and teammates can have a tomorrow that sounds even better than today.
Sebacia is a clinical-stage` private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia’s goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia’s microparticles technology was invented and licensed from Rice University` and the dermatology applications were further developed with researchers from and the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth` Georgia
Venus Concept is a leading developer and manufacturer of devices for the medical aesthetic market.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.
Renovia was formed to develop and commercialize products for better first-line diagnosis and treatment to improve the condition-specific quality of life for millions of women with pelvic floor disorders. Renovia`s technology enables treatment via precise visualization of pelvic movement in real-time during pelvic floor muscle training, while monitoring usage and progress over time. As a women`s health organization, Renovia is in pursuit of scalable and cost-effective care for pelvic floor disorders delivered through the power of digital health.